Steven Cohen's CTMX Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 7.81 M shares of CytomX Therapeutics, Inc. (CTMX) worth $29.29 M, representing 0.03% of the portfolio. First purchased in 2018-Q2, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in CTMX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2021, adding 6.21 M shares. Largest reduction occurred in Q3 2025, reducing 4.02 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's CytomX Therapeutics (CTMX) Holding Value Over Time
Track share changes against reported price movement
Quarterly CytomX Therapeutics (CTMX) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -64,357 | Reduce 0.82% | 7.81 M | $3.75 |
| Q1 2026 | +2.69 M | Add 51.76% | 7.88 M | $4.70 |
| Q4 2025 | +1.12 M | Add 27.55% | 5.19 M | $4.26 |
| Q3 2025 | -4.02 M | Reduce 49.68% | 4.07 M | $3.19 |
| Q2 2025 | +5.43 M | Add 205.08% | 8.08 M | $2.27 |
| Q4 2024 | +2.65 M | New Buy | 2.65 M | $1.03 |
| Q3 2022 | -2.75 M | Sold Out | 0 | $0.00 |
| Q2 2022 | -1.62 M | Reduce 37.09% | 2.75 M | $1.83 |
| Q1 2022 | -1.93 M | Reduce 30.65% | 4.37 M | $2.67 |
| Q3 2021 | -90,875 | Reduce 1.42% | 6.3 M | $5.09 |
| Q2 2021 | +58,900 | Add 0.93% | 6.39 M | $6.33 |
| Q1 2021 | +6.21 M | Add 4968.00% | 6.34 M | $7.73 |
| Q4 2020 | +125,000 | New Buy | 125,000 | $6.55 |
| Q3 2020 | -1.03 M | Sold Out | 0 | $0.00 |
| Q2 2020 | +816,842 | Add 377.18% | 1.03 M | $8.33 |
| Q1 2020 | -504,436 | Reduce 69.96% | 216,564 | $7.67 |
| Q4 2019 | +721,000 | New Buy | 721,000 | $8.31 |
| Q3 2019 | -330,498 | Sold Out | 0 | $0.00 |
| Q2 2019 | -295,151 | Reduce 47.18% | 330,498 | $11.22 |
| Q1 2019 | -838,147 | Reduce 57.26% | 625,649 | $10.75 |
| Q4 2018 | +136,056 | Add 10.25% | 1.46 M | $15.10 |
| Q3 2018 | +1.17 M | Add 739.43% | 1.33 M | $18.50 |
| Q2 2018 | +158,171 | New Buy | 158,171 | $22.86 |
Steven Cohen's CytomX Therapeutics Investment FAQs
Steven Cohen first purchased CytomX Therapeutics, Inc. (CTMX) in Q2 2018, acquiring 158,171 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held CytomX Therapeutics, Inc. (CTMX) for 25 quarters since Q2 2018.
Steven Cohen's largest addition to CytomX Therapeutics, Inc. (CTMX) was in Q1 2021, adding 6,335,000 shares worth $48.97 M.
According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 7,811,033 shares of CytomX Therapeutics, Inc. (CTMX), valued at approximately $29.29 M.
As of the Q2 2026 filing, CytomX Therapeutics, Inc. (CTMX) represents approximately 0.03% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in CytomX Therapeutics, Inc. (CTMX) was 8,084,623 shares, as reported at the end of Q2 2025.